Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease
Vaccinex, Inc. (Nasdaq: VCNX) announced that Elizabeth Evans, PhD, will chair a symposium and present a poster at the XV European Meeting on Glial Cells in Health and Disease, held virtually from July 5 to 9, 2021. The symposium focuses on targeting glial cell activation for neurodegenerative disease treatment. Dr. Evans will discuss the clinical evaluation of pepinemab, a SEMA4D blocking antibody for Huntington's Disease and its Phase 1b/2a trial in Alzheimer’s Disease. The poster presentation will detail findings from these clinical trials.
- Dr. Elizabeth Evans will present research on pepinemab, highlighting its potential in treating Huntington's and Alzheimer's diseases.
- The symposium and poster presentation may enhance investor interest and visibility in the scientific community.
- The forward-looking statements caution against uncertainties in clinical trials and regulatory approvals for pepinemab, potentially affecting timelines and outcomes.
ROCHESTER, N.Y., June 30, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that Elizabeth Evans, PhD, Chief Operating Officer and Senior Vice President, Discovery and Translational Medicine, will chair a Symposium and panel Q&A session and present a poster at the XV European Meeting on Glial Cells in Health and Disease, which is being held virtually from July 5 – 9, 2021.
Symposium and Panel Q&A Session
Session 18: Targeting glial cell activation for treatment of neurodegenerative disease
Date and time: Friday, July 9, 7:30am-8:30am ET (2:30pm-3:30pm CET)
Dr. Evans has organized and will co-chair with Dr Shawn Whitehead a live panel Q&A session. Panel participants and their respective presentations include:
- Seth A. Ament, PhD: Neuroimmune cell atlas for the human brain reveals gene networks activated in neurological disorders
- Elizabeth Evans, PhD: Targeting a signal of glial activation: clinical evaluation of Semaphorin 4D blocking antibody pepinemab
- Shawn Whitehead, PhD: White matter microglia activation and cognitive impairment
- Eduardo Zimmer, PhD: Imaging glucose metabolism
Note: all presentations are live online and available to conference participants effective June 28.
Poster Presentation
Session: Network and Poster Session E
Title: SEMA4D is a trigger of glial activation: clinical evaluation of pepinemab, a SEMA4D blocking antibody
Date and time: Friday, July 9, 11:30am-1:00pm ET (4:30pm-6:00pm CET)
This poster describes the mechanism of action of pepinemab and findings from the Company’s Phase 2 clinical trial of pepinemab in Huntington’s Disease. The poster also describes the design of a Phase 1b/2a clinical trial of pepinemab in Alzheimer’s Disease, which was recently initiated.
The full meeting program can be accessed here.
The presentation and poster will be available on the Vaccinex website following the conclusion of the meeting.
Forward Looking Statements
To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Such statements include, but are not limited to, statements about the Company’s plans, expectations and objectives with respect to the results and timing of clinical trials of pepinemab in various indications, the use and potential benefits of pepinemab in Huntington’s and Alzheimer’s disease and other indications, and other statements identified by words such as “may,” “will,” “appears,” “expect,” “planned,” “anticipate,” “estimate,” “intend,” “hypothesis,” “potential,” “advance,” and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of the Company’s research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, risks related to the Company’s dependence on its lead product candidate pepinemab, the ability to leverage its ActivMAb® platform, the impact of the COVID-19 pandemic, and other matters that could affect its development plans or the commercial potential of its product candidates. Except as required by law, the Company assumes no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in the Company’s periodic reports filed with the Securities and Exchange Commission (“SEC”) and the other risks and uncertainties described in the Company’s Form 10-K for year end December 31, 2021 and subsequent filings with the SEC.
Investor Contact
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
jeremy@lifesciadvisors.com
FAQ
What is Vaccinex's upcoming event?
Who will present at the Vaccinex symposium?
What will be discussed in the Vaccinex symposium?
What is pepinemab?
When will the poster presentation on pepinemab take place?
